- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03713632
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE)
A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a multicenter, randomized, double-blind, placebo-controlled, parallel group study with two secukinumab dose regimens in patients with moderate to severe HS. The study consisted of: screening (up to 4 weeks) treatment period 1 (16 weeks, active drug or placebo) and treatment period 2 (up to 1 year all patients on active drug); there was an optional extension study (NCT04179175). Adult males and females with moderate to severe HS were included, with a diagnosis of HS greater than 1 year prior to baseline. Dosing was once every 2 weeks, or once every 4 weeks via pre-filled syringe; periodic home-dosing is included.
In Treatment Period 1, participants were randomized to secukinumab Q2W, secukinumab Q4W, placebo Q2W or placebo Q4W in 1:1:0.5:0.5 ratio. In Treatment Period 2, at the Week 16 visit participants initially randomized to placebo were switched to one of the two active dose regimens (secukinumab Q2W or Q4W), while subjects randomized to secukinumab during Treatment Period 1 continued on the same dose.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Capital Federal, Argentina, C1023AAB
- Novartis Investigative Site
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentina, C1056ABJ
- Novartis Investigative Site
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, S2000DBS
- Novartis Investigative Site
-
-
-
-
-
Gent, Belgium, 9000
- Novartis Investigative Site
-
Liege, Belgium, 4000
- Novartis Investigative Site
-
-
-
-
-
Pleven, Bulgaria, 5800
- Novartis Investigative Site
-
Sofia, Bulgaria, 1431
- Novartis Investigative Site
-
-
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 7G1
- Novartis Investigative Site
-
Richmond Hill, Ontario, Canada, L4C 9M7
- Novartis Investigative Site
-
-
Quebec
-
Drummondville, Quebec, Canada, J2B 5L4
- Novartis Investigative Site
-
Saint Jerome, Quebec, Canada, J7Z 3B8
- Novartis Investigative Site
-
-
-
-
-
Bogota, Colombia, 110221
- Novartis Investigative Site
-
-
Atlantico
-
Barranquilla, Atlantico, Colombia, 080002
- Novartis Investigative Site
-
-
-
-
HRV
-
Zagreb, HRV, Croatia, 10000
- Novartis Investigative Site
-
-
-
-
-
Jihlava, Czechia, 586 33
- Novartis Investigative Site
-
-
Czech Republic
-
Usti nad Labem, Czech Republic, Czechia, 400 11
- Novartis Investigative Site
-
-
-
-
-
Aarhus, Denmark, 8000
- Novartis Investigative Site
-
Copenhagen NV, Denmark, 2400
- Novartis Investigative Site
-
-
-
-
-
Antony, France, 92160
- Novartis Investigative Site
-
Martigues, France, 13500
- Novartis Investigative Site
-
Nice, France, 06202
- Novartis Investigative Site
-
Reims, France, 51100
- Novartis Investigative Site
-
Rouen Cedex, France, 76031
- Novartis Investigative Site
-
Saint Mande, France, 94160
- Novartis Investigative Site
-
Saint-Etienne, France, 42055
- Novartis Investigative Site
-
-
Haute Vienne
-
Limoges, Haute Vienne, France, 87000
- Novartis Investigative Site
-
-
Val De Marne
-
Toulon Cedex 9, Val De Marne, France, 83800
- Novartis Investigative Site
-
-
-
-
-
Berlin, Germany, 13353
- Novartis Investigative Site
-
Berlin, Germany, 10789
- Novartis Investigative Site
-
Dessau Rosslau, Germany, 06847
- Novartis Investigative Site
-
Erlangen, Germany, 91054
- Novartis Investigative Site
-
Hamburg, Germany, 20246
- Novartis Investigative Site
-
Heidelberg, Germany, 69120
- Novartis Investigative Site
-
Muenchen, Germany, 81377
- Novartis Investigative Site
-
Muenster, Germany, 48149
- Novartis Investigative Site
-
Schwerin, Germany, 19055
- Novartis Investigative Site
-
Wuerzburg, Germany, 97080
- Novartis Investigative Site
-
-
-
-
-
Athens, Greece, 161 21
- Novartis Investigative Site
-
-
GR
-
Thessaloniki, GR, Greece, 564 03
- Novartis Investigative Site
-
-
-
-
-
Guatemala City, Guatemala, 01010
- Novartis Investigative Site
-
Guatemala City, Guatemala, 1015
- Novartis Investigative Site
-
-
-
-
-
Debrecen, Hungary, 4032
- Novartis Investigative Site
-
Kaposvar, Hungary, 7400
- Novartis Investigative Site
-
Szeged, Hungary, 6725
- Novartis Investigative Site
-
-
-
-
Maharashtra
-
Nagpur, Maharashtra, India, 440009
- Novartis Investigative Site
-
Navi Mumbai, Maharashtra, India, 400 706
- Novartis Investigative Site
-
-
-
-
-
Ramat Gan, Israel, 52621
- Novartis Investigative Site
-
Tel Aviv, Israel, 6423906
- Novartis Investigative Site
-
-
-
-
-
Napoli, Italy, 80131
- Novartis Investigative Site
-
-
AN
-
Ancona, AN, Italy, 60126
- Novartis Investigative Site
-
-
FE
-
Cona, FE, Italy, 44100
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italy, 00133
- Novartis Investigative Site
-
-
-
-
-
Saida, Lebanon, 652
- Novartis Investigative Site
-
-
-
-
LTU
-
Kaunas, LTU, Lithuania, LT 50161
- Novartis Investigative Site
-
-
Vilniaus
-
Vilnius, Vilniaus, Lithuania, LT 08661
- Novartis Investigative Site
-
-
-
-
-
Johor Bahru, Malaysia, 80100
- Novartis Investigative Site
-
Penang, Malaysia, 10990
- Novartis Investigative Site
-
-
Wilayah Persekutuan
-
Kuala Lumpur, Wilayah Persekutuan, Malaysia, 50586
- Novartis Investigative Site
-
-
-
-
-
Bergen op Zoom, Netherlands, 4624 VT
- Novartis Investigative Site
-
-
-
-
-
Makati City, Philippines, 1220
- Novartis Investigative Site
-
-
-
-
-
Lodz, Poland, 90-436
- Novartis Investigative Site
-
Rzeszow, Poland, 35 055
- Novartis Investigative Site
-
Warszawa, Poland, 04141
- Novartis Investigative Site
-
-
-
-
-
Chelyabinsk, Russian Federation, 454048
- Novartis Investigative Site
-
Saint Petersburg, Russian Federation, 191123
- Novartis Investigative Site
-
Smolensk, Russian Federation, 214031
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 119074
- Novartis Investigative Site
-
Singapore, Singapore, 169608
- Novartis Investigative Site
-
Singapore, Singapore, 308205
- Novartis Investigative Site
-
-
-
-
-
Presov, Slovakia, 081 81
- Novartis Investigative Site
-
-
Slovak Republic
-
Banska Bystrica, Slovak Republic, Slovakia, 97401
- Novartis Investigative Site
-
-
-
-
Gauteng
-
Pretoria, Gauteng, South Africa, 0001
- Novartis Investigative Site
-
Soweto, Gauteng, South Africa, 2013
- Novartis Investigative Site
-
-
-
-
-
Granada, Spain, 18012
- Novartis Investigative Site
-
Las Palmas de Gran Canaria, Spain, 35010
- Novartis Investigative Site
-
Madrid, Spain, 28006
- Novartis Investigative Site
-
Madrid, Spain, 28009
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08003
- Novartis Investigative Site
-
-
Valencia
-
Manises, Valencia, Spain, 46940
- Novartis Investigative Site
-
-
-
-
-
Lausanne, Switzerland, 1011
- Novartis Investigative Site
-
Zurich, Switzerland, CH-8091
- Novartis Investigative Site
-
-
-
-
-
Altunizade, Turkey, 34662
- Novartis Investigative Site
-
Izmir, Turkey, 35040
- Novartis Investigative Site
-
Talas / Kayseri, Turkey, 38039
- Novartis Investigative Site
-
-
TUR
-
Istanbul, TUR, Turkey, 34098
- Novartis Investigative Site
-
-
-
-
-
Birmingham, United Kingdom, B15 2TH
- Novartis Investigative Site
-
Harrogate, United Kingdom, HG2 7SX
- Novartis Investigative Site
-
London, United Kingdom, SE1 9RT
- Novartis Investigative Site
-
London, United Kingdom, E1 1BB
- Novartis Investigative Site
-
-
West Midlands
-
Dudley, West Midlands, United Kingdom, DY1 2HQ
- Novartis Investigative Site
-
-
West Yorkshire
-
Bradford, West Yorkshire, United Kingdom, BD5 0NA
- Novartis Investigative Site
-
-
-
-
California
-
San Diego, California, United States, 92103
- Novartis Investigative Site
-
Whittier, California, United States, 92677
- Novartis Investigative Site
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- Novartis Investigative Site
-
Tampa, Florida, United States, 33609
- Novartis Investigative Site
-
-
Georgia
-
Sandy Springs, Georgia, United States, 30328
- Novartis Investigative Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46256
- Novartis Investigative Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Novartis Investigative Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Novartis Investigative Site
-
Saint Louis, Missouri, United States, 63104
- Novartis Investigative Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68144
- Novartis Investigative Site
-
-
New York
-
New York, New York, United States, 10029
- Novartis Investigative Site
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Novartis Investigative Site
-
-
Texas
-
Bellaire, Texas, United States, 77401
- Novartis Investigative Site
-
Pflugerville, Texas, United States, 78660
- Novartis Investigative Site
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Novartis Investigative Site
-
-
-
-
-
Hanoi, Vietnam, 100000
- Novartis Investigative Site
-
Ho Chi Minh, Vietnam, 7000
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- -Written informed consent must be obtained before any assessment is performed.
- Male and female patients ≥ 18 years of age.
- Diagnosis of HS ≥ 1 year prior to baseline.
- Patients with moderate to severe HS defined as:
- A total of at least 5 inflammatory lesions, i.e. abscesses and/or inflammatory nodules AND
- Inflammatory lesions should affect at least 2 distinct anatomic areas
- Patients agree to daily use of topical over-the-counter antiseptics on the areas affected by HS lesions while on study treatment.
Exclusion Criteria:
- Total fistulae count ≥ 20 at baseline.
- Any other active skin disease or condition that may interfere with assessment of HS.
- Active ongoing inflammatory diseases other than HS that require treatment with prohibited medications.
- Use or planned use of prohibited treatment. Washout periods detailed in the protocol have to be adhered to.
- History of hypersensitivity to any of the study drug constituents.
- History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
- Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Secukinumab 1
Secukinumab 300mg every 2 weeks
|
Secukinumab 300mg every 2 or every 4 weeks
|
Active Comparator: Secukinumab 2
Secukinumab 300mg every 4 weeks
|
Secukinumab 300mg every 2 or every 4 weeks
|
Placebo Comparator: Placebo 1
Placebo group to secukinumab 300mg every 2 weeks
|
Placebo 300mg every 2 or every 4 weeks
|
Placebo Comparator: Placebo 2
Placebo group to secukinumab 300mg every 4 weeks
|
Placebo 300mg every 2 or every 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)
Time Frame: 16 weeks
|
HiSCR50 at Week 16 is defined as at least a 50% decrease in Abscess and inflammatory Nodule (AN) count compared to baseline with no increase in the number of abscesses and/or in the number of draining fistulas from baseline to Week 16. The baseline is defined as the last assessment (including unscheduled visits) obtained before/on the day of the first administration of the study treatment, or on the randomization date if there had been no drug administration. This endpoint was analyzed by logistic regression. |
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change From Baseline in AN Count
Time Frame: Baseline, 16 weeks
|
Percent change from baseline in abscesses and inflammatory nodules (AN) count.
This endpoint was analyzed by analysis of covariance.
|
Baseline, 16 weeks
|
Percentage of Participants With Hidradenitis Suppurativa (HS) Flares
Time Frame: 16 weeks
|
Percentage of participants who experience at least one flare over 16 weeks. A flare is defined as at least a 25% increase in abscesses and inflammatory nodules (AN) count with a minimum increase of 2 AN relative to baseline. This endpoint was analyzed by logistic regression. |
16 weeks
|
Percentage of Participants Achieving NRS30
Time Frame: 16 weeks
|
Patients achieving Numerical Rating Scale score of 30 (NRS30) at week 16, defined as at least a 30% reduction and at least one unit reduction from baseline in the Patient's Global assessment of Skin Pain (where range 0 [no skin pain] to 10 [worst skin pain]). This endpoint was analyzed by logistic regression. |
16 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Study Lead Study Director, Novartis
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAIN457M2302
- 2018-002062-39 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hidradenitis Suppurativa
-
Yale UniversityNot yet recruitingHidradenitis Suppurativa | Hidradenitis Suppurativa, Acne Inversa | Hidradenitis Suppurativa \(HS\)United States
-
Boehringer IngelheimRecruiting
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Canada, Bulgaria, Italy, Spain, Germany, Poland, France, Australia, Denmark, United Kingdom
-
Novartis PharmaceuticalsAvailableHidradenitis Suppurativa (HS)
-
AbbVie (prior sponsor, Abbott)CompletedHidradenitis Suppurativa (HS)
-
InflaRx GmbHQuintiles, Inc.CompletedHidradenitis Suppurativa (HS)United States, Bulgaria, Canada, Denmark, France, Germany, Greece, Netherlands, Poland
-
Erasmus Medical CenterNot yet recruitingHidradenitis Suppurativa, Acne Inversa
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Canada, Czechia, Spain, Germany, Poland, Netherlands, Belgium, France, Greece, Japan, Austria
-
Wake Forest University Health SciencesActive, not recruiting
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Austria, Belgium, Canada, Germany, Poland, Spain, Australia, Denmark, France, United Kingdom, Japan, Bulgaria, Netherlands, Czechia, Greece, Italy
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States